Padagis unveils FDA approved AB rated generic Doxil
22 October 2021 -

Healthcare products company Padagis reported on Thursday the launch of the US FDA approved AB-rated generic version of Doxil (Doxorubicin Liposome Injection) under its partnership with Ayana Pharma Ltd.

The company added that the Doxil Liposome Injection is an anthracycline topoisomerase inhibitor indicated for Ovarian Cancer, AIDS-related Kaposi's Sarcoma as well as Multiple Myeloma.

For the 12 months ending August 2021, the annual market sales for Doxil Liposome Injection were about USD98m as measured by IQVIA, added the company.

According to Padagis' EVP Colter VanStedum, Doxil's generic launch is the culmination of several years of working with the Ayana team to bring this highly complex product to market, and to its customers and patients in need of a high-quality generic alternative.